Revelation Biosciences, Inc. SEC filings REVB
Revelation Biosciences, Inc. has 389 filings in SEC EDGAR's recent list, going back to May 14, 2020. Its latest annual report, Form ARS, was filed on May 11, 2026 for the period ended May 11, 2026. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Apr 15, 2026 | — |
| 424B3 | Prospectus | Feb 11, 2026 | — |
| S-3 | Shelf registration | Jan 30, 2026 | — |
| S-8 | Employee stock plan registration | Nov 12, 2025 | — |
| 424B3 | Prospectus | Sep 30, 2025 | — |
| S-3/A | Filing | Sep 30, 2025 | — |
| S-3 | Shelf registration | Sep 16, 2025 | — |
| 424B3 | Prospectus | May 29, 2025 | — |
| S-1/A | Amended registration statement | May 23, 2025 | — |
| S-1 | Registration statement | May 20, 2025 | — |
| 424B3 | Prospectus | Dec 20, 2024 | — |
| S-3/A | Filing | Dec 19, 2024 | — |
| S-3 | Shelf registration | Dec 12, 2024 | — |
| 424B3 | Prospectus | Sep 13, 2024 | — |
| S-3 | Shelf registration | Sep 3, 2024 | — |
| S-3 | Shelf registration | Jul 19, 2024 | — |
| S-8 | Employee stock plan registration | Jun 18, 2024 | — |
| 424B3 | Prospectus | Feb 2, 2024 | — |
| S-1/A | Amended registration statement | Jan 30, 2024 | — |
| S-1/A | Amended registration statement | Jan 29, 2024 | — |
| S-1 | Registration statement | Dec 22, 2023 | — |
| S-8 | Employee stock plan registration | Aug 11, 2023 | — |
| 424B3 | Prospectus | Feb 13, 2023 | — |
| S-1MEF | Registration statement | Feb 9, 2023 | — |
| S-1/A | Amended registration statement | Feb 9, 2023 | — |
| S-1/A | Amended registration statement | Feb 1, 2023 | — |
| S-1 | Registration statement | Nov 29, 2022 | — |
| S-1/A | Amended registration statement | Nov 16, 2022 | — |
| S-1 | Registration statement | Oct 31, 2022 | — |
| 424B3 | Prospectus | Jul 27, 2022 | — |
| S-1/A | Amended registration statement | Jul 25, 2022 | — |
| S-1/A | Amended registration statement | Jul 21, 2022 | — |
| S-1/A | Amended registration statement | Jul 18, 2022 | — |
| S-1 | Registration statement | Jul 13, 2022 | — |
| 424B3 | Prospectus | Jun 27, 2022 | — |
| S-8 | Employee stock plan registration | May 31, 2022 | — |
| S-1 | Registration statement | May 31, 2022 | — |
| 424B3 | Prospectus | Feb 10, 2022 | — |
| S-1 | Registration statement | Jan 28, 2022 | — |
| 424B3 | Prospectus | Dec 16, 2021 | — |
| S-4/A | Registration statement | Dec 13, 2021 | — |
| S-4/A | Registration statement | Dec 7, 2021 | — |
| S-4/A | Registration stateent | Nov 4, 2021 | — |
| S-4 | Registration for a merger or exchange | Sep 20, 2021 | — |
| 424B4 | Prospectus | Oct 13, 2020 | — |
| S-1/A | Amended registration statement | Sep 21, 2020 | — |
| S-1/A | Amended registration statement | Aug 26, 2020 | — |
| S-1/A | Amended registration statement | Aug 19, 2020 | — |
| S-1/A | Amended registration statement | Aug 11, 2020 | — |
| S-1 | Registration statement | Jul 29, 2020 | — |
Showing 50 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- REVB (Nasdaq), REVBW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1810560
- Former names
- Petra Acquisition Inc. (until Jan 11, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.